Edition:
United States

Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis


Wednesday, 8 Feb 2017 08:00am EST 

Veracyte Inc : Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics . Says quest diagnostics is expected to begin offering test to its customers nationally in Q2 of 2017 . Says financial and other terms of agreement were not disclosed. .Physician clients of quest diagnostics will be able to order test on behalf of patients, refer patient specimens to co for genomic testing.